» Articles » PMID: 22019035

Diabetes Mellitus, Race and the Odds of High Grade Prostate Cancer in Men Treated with Radiation Therapy

Overview
Journal J Urol
Publisher Wolters Kluwer
Specialty Urology
Date 2011 Oct 25
PMID 22019035
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Black men present more frequently with high grade prostate cancer and are more likely to have diabetes mellitus. We evaluated whether there is an independent association between diabetes mellitus and the risk of high grade prostate cancer in men diagnosed with prostate cancer and treated with radiation therapy.

Materials And Methods: A polychotomous logistic regression analysis was performed to evaluate whether a diagnosis of diabetes mellitus was associated with the odds of Gleason score 7 or 8-10 prostate cancer in a cohort of 16,286 men, adjusting for black race, advancing age, prostate specific antigen and digital rectal examination findings.

Results: Black men (adjusted OR 1.84, 95% CI 1.08-3.13, p = 0.024) and nonblack men (adjusted OR 1.59, 95% CI 1.33-1.89, p <0.001) with diabetes were more likely to have Gleason score 8-10 vs 6 or less prostate cancer than nondiabetic men. However, this was not true for Gleason score 7 vs 6 or less prostate cancer. Black race was significantly associated with Gleason score 7 vs 6 or less prostate cancer in men without and with diabetes (adjusted OR 1.38, 95% CI 1.17-1.63, p <0.001 and 1.61, 95% CI 1.17-2.21, p = 0.003, respectively). Black race was also associated with Gleason score 8-10 vs 6 or less prostate cancer in men without and with diabetes (adjusted OR 1.36, 95% CI 1.01-1.83, p = 0.04 and 1.58, 95% CI 0.98-2.53, p = 0.06, respectively).

Conclusions: In a cohort of men undergoing radiotherapy for prostate cancer the diagnosis of diabetes mellitus was significantly associated with an increased risk of being diagnosed with Gleason score 8-10 prostate cancer independent of black race.

Citing Articles

Health-related quality of life in ethnically diverse Black prostate cancer survivors: a convergent parallel mixed-methods approach.

Ogunsanya M, Kaninjing E, Ellis T, Morton D, McIntosh A, Zhao J Qual Life Res. 2024; 33(10):2705-2719.

PMID: 39008143 PMC: 11855403. DOI: 10.1007/s11136-024-03718-9.


Racial disparity in prostate cancer in the African American population with actionable ideas and novel immunotherapies.

Dovey Z, Nair S, Chakravarty D, Tewari A Cancer Rep (Hoboken). 2021; 4(5):e1340.

PMID: 33599076 PMC: 8551995. DOI: 10.1002/cnr2.1340.


TGF-β and microRNA Interplay in Genitourinary Cancers.

Boguslawska J, Kryst P, Poletajew S, Piekielko-Witkowska A Cells. 2019; 8(12).

PMID: 31842336 PMC: 6952810. DOI: 10.3390/cells8121619.


Impact of metabolic disorders on prostate cancer growth: Androgen and insulin resistance perspectives.

Yanase T, Kawanami T, Tanaka T, Tanabe M, Nomiyama T Reprod Med Biol. 2017; 16(3):252-257.

PMID: 29259475 PMC: 5715889. DOI: 10.1002/rmb2.12039.


The impact of metformin use on the risk of prostate cancer after prostate biopsy in patients with high grade intraepithelial neoplasia.

DellAtti L, Galosi A Int Braz J Urol. 2017; 44(1):69-74.

PMID: 29211393 PMC: 5815534. DOI: 10.1590/S1677-5538.IBJU.2017.0046.